 Apellis Pharmaceuticals Inc NASDAQ: APLS and Swedish Orphan Biovitrum AB SOBI have reported positive top-line results from the Phase 3 PRINCE study evaluating Empaveli pegcetacoplan in treatment naïve paroxysmal nocturnal hemoglobinuria PNH patients. Empaveli demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization and reduction in lactate dehydrogenase LDH compared to standard of care, which did not include complement inhibitors, at Week 26. 